🚀 VC round data is live in beta, check it out!
Tasly Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tasly and similar public comparables like BioArctic, Alumis, Sinocelltech Group, Jilin Aodong and more.
Tasly Overview
About Tasly
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
Founded
1998
HQ
Employees
3.4K
Website
Sectors
Financials (LTM)
EV
$3B
Tasly Financials
Tasly reported last 12-month revenue of $1B and EBITDA of $279M.
In the same LTM period, Tasly generated $828M in gross profit, $279M in EBITDA, and $170M in net income.
Revenue (LTM)
Tasly P&L
In the most recent fiscal year, Tasly reported revenue of $1B and EBITDA of $269M.
Tasly expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $828M | XXX | $807M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $279M | XXX | $269M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $170M | XXX | $162M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tasly Stock Performance
Tasly has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Tasly's stock price is $2.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTasly Valuation Multiples
Tasly trades at 2.4x EV/Revenue multiple, and 10.5x EV/EBITDA.
EV / Revenue (LTM)
Tasly Financial Valuation Multiples
As of April 19, 2026, Tasly has market cap of $3B and EV of $3B.
Equity research analysts estimate Tasly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tasly has a P/E ratio of 18.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 10.5x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | 14.2x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | 3.6x | XXX | XXX | XXX |
| P/E | 18.4x | XXX | 19.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 19.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tasly Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tasly Margins & Growth Rates
Tasly's revenue in the last 12 month grew by 10%.
Tasly's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Tasly's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tasly's rule of X is 47% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Tasly Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 36% | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tasly Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tasly | XXX | XXX | XXX | XXX | XXX | XXX |
| BioArctic | XXX | XXX | XXX | XXX | XXX | XXX |
| Alumis | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Jilin Aodong | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcutis Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tasly M&A Activity
Tasly acquired XXX companies to date.
Last acquisition by Tasly was on XXXXXXXX, XXXXX. Tasly acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tasly
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTasly Investment Activity
Tasly invested in XXX companies to date.
Tasly made its latest investment on XXXXXXXX, XXXXX. Tasly invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tasly
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tasly
| When was Tasly founded? | Tasly was founded in 1998. |
| Where is Tasly headquartered? | Tasly is headquartered in China. |
| How many employees does Tasly have? | As of today, Tasly has over 3K employees. |
| Is Tasly publicly listed? | Yes, Tasly is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Tasly? | Tasly trades under 600535 ticker. |
| When did Tasly go public? | Tasly went public in 2002. |
| Who are competitors of Tasly? | Tasly main competitors are BioArctic, Alumis, Sinocelltech Group, Jilin Aodong. |
| What is the current market cap of Tasly? | Tasly's current market cap is $3B. |
| What is the current revenue of Tasly? | Tasly's last 12 months revenue is $1B. |
| What is the current revenue growth of Tasly? | Tasly revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Tasly? | Current revenue multiple of Tasly is 2.4x. |
| Is Tasly profitable? | Yes, Tasly is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tasly? | Tasly's last 12 months EBITDA is $279M. |
| What is Tasly's EBITDA margin? | Tasly's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Tasly? | Current EBITDA multiple of Tasly is 10.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.